

Comparative Study Between Different
Types of Priming Solution of
Extracorporeal Circulation on
Coagulation Profile In Open Heart
Surgery

Thesis

*Submitted in the Partial Fulfillment of the M.D. Degree
in Anesthesiology*

Presented By

Ahmed Abd Elkader ElEsawy
(M.B., B.Ch., M.Sc.)

Under Supervision of

Prof. Dr. Bahira Mohamed Tawfik
*Professor of Anesthesia and Intensive Care
Faculty of Medicine - Ain Shams University*

Dr. Khaled Hassan Saad
*Lecturer of Anesthesia and Intensive Care
Faculty of Medicine - Ain Shams University*

Dr. Mohamed Anwar El Shafi
*Lecturer of Anesthesia and Intensive Care
Faculty of Medicine - Ain Shams University*

Faculty of Medicine
Ain Shams University

۲.۰.۵



Acknowledgment

*First, Thanks are all due to **God** for blessing this work until it has reached its end, as a part of his generous help throughout my life.*

*I would like to express my deepest gratitude to **Prof. Dr. Bahira Mohamed Tawfik**, Professor of Anesthesia and Intensive Care, Faculty of Medicine, Ain Shams University, for her great support and continuous encouragement through this whole work, it is a great honor to work under her guidance and supervision.*

*I am truly grateful to **Dr. Khaled Hassan Saad**, Lecturer of Anesthesia and Intensive Care, Faculty of Medicine, Ain Shams University, for his close supervision, sincere help, valuable suggestion and continuous encouragement through the whole work,*

*My deepest appreciation and grateful thanks are due to **Dr. Mohamed Anwar El Shafei**, Lecturer of Anesthesia and Intensive Care, Faculty of Medicine, Ain Shams University, for his kind advice and great efforts throughout this work,*



List of Content

	<u>Page</u>
• Introduction & Aim of the Study	١
• Review of Literature:	
- Physiology of coagulation and hemostasis	٤
- Hemostasis and Cardiopulmonary Bypass	١٥
- Anticoagulation During Vardiopulmonary Bypass	٢٩
- Hemodilution and Complication of Cardiopulmonary Bypass.....	٣٦
- Priming Solution.....	٤٠
• Patients and Methods	٤٦
• Results	٥٥
• Discussion	٨١
• Summary	٩١
• References	٩٣
• Arabic Summary	--

List of Tables

<i>Tab. No.</i>	<i>Title</i>	<i>Page</i>
١.	Factors affecting hemostasis in pediatric patients	٢٦
٢.	Comparison between the three groups regarding patient's data ..	٥٥
٣.	Comparison between the three groups regarding operation data.....	٥٦
٤.	Comparison between the three groups regarding the hemoglobin	٥٨
٥.	Comparison between the three groups regarding hematocrite	٦٠
٦.	Comparison between the three groups regarding prothrombin time	٦٢
٧.	Comparison between the three groups regarding activated partial thromboplastin time	٦٤
٨.	Comparison between the three groups regarding activated Clotting time	٦٦
٩.	Comparison between the three groups regarding bleeding time	٦٨
١٠.	Comparison between the three groups regarding platelet count	٧٠
١١.	Comparison between the three groups regarding platelet aggregation	٧٣
١٢.	Comparison between the three groups regarding fibrinogen.....	٧٥
١٣.	Comparison between the three groups regarding fibrin degradation products.....	٧٧
١٤.	Comparison between the three groups regarding factor VIII	٧٨
١٥.	Comparison between the three groups regarding fluid balance during CPB	٨٠
١٦.	Comparison between the three groups regarding blood loss (ml)	٨٠

List of Figures

<i>Fig. No.</i>	<i>Title</i>	<i>Page</i>
١.	Hemostasis	٥
٢.	Platelet function	٧
٣.	The intrinsic and extrinsic pathways of coagulation	٩
٤.	The fibrinolytic system	١٢
٥.	Schematic draws of platelet activation during CPB	٢١
٦.	Scheme for fibrinolytic activation during CPB	٢٤
٧.	A suggested protocol for CPB anticoagulation and its renasal....	٣٣
٨.	Comparison between the three groups regarding the hemoglobin concentration	٥٩
٩.	Comparison between the three groups regarding the hematocyte %	٦١
١٠.	Comparison between the three groups regarding the prothrombin time %	٦٣
١١.	Comparison between the three groups regarding the activated partial thromboplastin time	٦٥
١٢.	Comparison between the three groups regarding the activated clotting time	٦٧
١٣.	Comparison between the three groups regarding the bleeding time	٦٩
١٤.	Comparison between the three groups regarding the platelet count	٧١
١٥.	Comparison between the three groups regarding the platelet aggregation	٧٤
١٦.	Comparison between the three groups regarding the fibrinogen	٧٦
١٧.	Comparison between the three groups regarding the factor VIII	٧٩

List of Abbreviations

ACT	Activated clotting time
ADP	Adenosine diphosphate
APTT	Activated partial thromboplastin time
AT III	Antithrombin III
ATP	Adenosine triphosphate
BT	Bleeding time
B-TG	B-thromboglobulin
CPB	Cardiopulmonary bypass
ECC	Extracorporeal circulation]
FDP	Fibrin degradation product
GP	Glycoprotein
Hb	Hemoglobin
HES	Hydroxyethyl starch
HMW	High molecular weight
ICU	Intensive care unit
PAIS	Plasminogen-activator inhibitors
PGI ₁	Prostaglandin I ₁
PT	Prothrombin time
TPA	Tissue plasminogen activator
TT	Thrombin time
Tx A ₁	Thromboxane A ₁
VWF	Von Willebrand factor
X _a	Activated factor X

Introduction

The technique of Cardiopulmonary Bypass (CPB) is a common procedure in cardiac surgery. Although (CPB) is considered safe, it disturbs the hemostatic system, which may cause severe bleeding complications, thrombocytopenia, and/ or platelets dysfunction (*Menichetti et al., 1997*).

These complication are though to be due to exposure to artificial surface of pump circuit, surgical traumas, hemodilution, intra-operative high dose of heparin, depth of hypothermia (*Condo et al., 1994*).

In addition to passive dilutional effect, prime composition also impact hemostasis either Ringer's solution or High molecular weight hydroxyethyl starch or Albumin (*Kuitunen et al., 1993*).

The solution used to prime the CPB varies widely, there is still no consensus in the ideal priming solution, particularly with regard to hemostasis (*Tobias, 1997*).

During CPB, blood is continuously exposed to the nonendothelial, synthetic surface of the extracorporeal oxygenation circuit (*Westaby, 1999*).

Platelets adhesion and protein denaturation are possible sequelae of this blood/surface contact. Denaturated protein result in cellular aggregation, sledging and microthrombosis. Denaturation of red cell membrane induces a release of

adenosine diphosphate (ADP), which leads to aggregation. The vicious cycle is continued as aggregated platelets release more ADP, promoting further platelets aggregation (*Born et al., 1997*).

Preexpose of synthetic surface to Albumin (coating) decrease the affinity of platelets to synthetic surface (*Campbel, and Addonizio, 1988*). Platelets granule release would be reduced and morphologic integrity of platelets would be preserved when using surface absorbed Albumin (*Addonizio et al., 1999*).

Impairment in platelets function secondary to CPB is one of the most important reasons for enhanced and prolonged bleeding in open heart surgery (*Addonizio et al., 1999*).

Approximately 10% - 20% of patients undergoing cardiac surgery procedures exhibit inadequate hemostasis varying in its duration and severity. This patient often require treatment with hemologous blood or blood products (*Ellison and Jones, 1999*). Surgical reexploration is required in approximately 3% of these patient (*Harker, 1997*).

Hydroxyethyl starch (HES-heastril) has been shown to be an effective expender of the intravascular volume (*Halonen et al., 1988*). However like other artificial colloids, HES may have adverse effect on hemostasis (*Strauss et al., 1998*). Heastril may affect the hemostasis mechanism by depressing platelets function, by lowering plasma levels of clotting factors via haemodilutional or via other mechanism and finally, by increase

fibrinolysis. These effect of HES often result in varying degrees of subclinical coagulopathy (*Stump et al., ۱۹۸۵*).

The ideal choice of priming solution of CPB and its influences on the hemostasis system are not clear. Addition of Albumin was reported to inhibit platelets damaging by blood surface interactions(coating) (*Kirklin et al., ۱۹۸۷*).

Aim of the Work:

The aim of these study is to compare the effect of different types of priming solution of CPB including Ringer's, Haestril, Albumin on coagulation profile.

Physiology of Coagulation and Hemostasis in Adults and Pediatrics

The hemostatic system serves to minimize blood loss from the vascular space and maintains the blood as a cellular and protein suspension to flow to peripheral tissues. Normal hemostasis is dependent on the interactions of the components of blood vessel walls with the circulating cellular elements and proteins. Cardiac surgery would not be possible without some control of the hemostatic system to prevent thrombosis during cardiopulmonary bypass (CPB) and to decrease post-operative blood loss (*Spiess and Chang, 1993*).

The hemostatic system is divided into 3 subdivisions i.e. vascular system, platelets and blood coagulation system. Synopsis of hemostasis is illustrated in Fig. (1).

The Vascular System:

The vessel wall is a metabolically and physically active organ system, which affects the hemodynamic function, thrombosis and hemostasis. In the resting state, blood is actively maintained in a liquid form by endothelial cells and circulating plasma protein inhibitors, when the vascular integrity is disrupted or the endothelium becomes inflamed coagulation is initiated. Vasoconstriction is the immediate local response of the vascular system to a break in integrity. The

vascular smooth muscle cells are responsible for maintenance of vascular tone and synthesis of elastin, collagen and glycosaminoglycan (*Boyle et al., 1994*). Endothelial cells synthesize enzymes, coagulation factors, proteins and prostaglandins e.g. PGI₂, thrombomodulin, heparin like substances and plasminogen activators, which, act to prevent thrombosis. It also synthesize fibronectin, Von Willebrand factor, lipoprotein lipase, plasminogen activator inhibitors and endothelin (a protein vasoconstrictor peptide). The eicosanoids prostacyclin and thromboxane as produced by endothelial cells influence the interaction between platelets and vessels wall (*Havel et al., 1994*).

Fig. (1): Hemostasis: a synopsis. The sequential events comprising the process of hemostasis are shown in the center following the central solid arrows. At each step activators (dotted arrows on the left) and inhibitors (dashed arrows on the right) interact to provide a finely

controlled process. VWF, Von Willebrand factor; PGIs, prostaglandin Is; ADP, adenosine diphosphate (*Colman et al., 1999*).

Platelets:

The primary process of hemostatic phases after immediate vasospasm is the formation of hemostatic plug. This is achieved by platelet adhesion, aggregation, and release of granules and other products. This initiation of the hemostatic process is followed by the activation of the clotting process to produce fibrin (*O'Reilly, 1994*).

The first step in this process is the interaction between platelets and thrombogenic surface, so platelets adhere to the collagen of the damaged endothelial cells or subendothelial layer specifically to fibrinogen and by Von Willebrand factor. The receptor site at the platelet is the glycoprotein Ib (GP I b) which is the primary target for this factor (*Sakariassen et al., 1997*).

Platelets undergo a shape change and spread out to cover more of the thrombogenic surface. Adherent platelets release Adenosine diphosphate (ADP) and thromboxane A₂ (TxAs), these substances are involved in the activation of non stimulated platelets (Fig. 2) (*Stein et al., 1999*).

Glycoproteins (GP II b and GP III a) on the surface of platelet thus activated and bind tightly to fibrinogen. The activated (GP II b/III a), complex is termed the "fibrinogen receptor" so adherence requires platelet activation, adsorption of fibrinogen into the surface which is also essential for the

process of platelet to platelet binding that occurs during irreversible aggregation, and the presence of platelet membrane fibrinogen receptors, Von Willebrand factor is also critical to platelet adhesion and therefore is critical for the arrest of bleeding (**Roth, 1991**).

Fig. (1): Platelet function. The phases of platelet involvement in the early stage on thrombus formation are shown. Platelets initially adhere to subendothelial proteins such as collagen and Von Willebrand factor. They undergo a shape change, spread out, and release adenosine diphosphate (ADP) and thromboxane A₂ (TxA₂), which attract and activate other platelets, causing aggregation. Thrombus formation is completed by the formation of cross-linked fibrin strands. Endogenous inhibitors of thrombosis are shown (**Stein et al., 1999**).

Platelets contain three types of granules, dense, alpha and lysosomes. The **dense** granules contain adenosine diphosphate (ADP), adenosine triphosphate (ATP), inorganic phosphate and

serotonin. **Alpha** granules contain multiple proteins, including coagulation factors, platelet specific proteins such as platelet-derived growth factor, and the glycoproteins. Lysosomes contain acid hydrolyses (*O'Reilly, 1991*). Thrombin and collagen induce secretion of substances from all three granule types, while epinephrine, ADP, and TxA₂ induce secretion from alpha and dense granules only. All these contents particularly ADP induce further platelet aggregation. Activated platelets also secrete TxA₂, which is a powerful platelet activator and aggregant (*Spiess and Change, 1992*).

Although thrombin is a powerful inducer of platelet aggregation, and stimulates synthesis of TxA₂, which induces thrombogenesis and vasoconstriction, it stimulates the synthesis of prostacyclin (PGI₂) from vessel wall, which inhibits thrombogenesis and causes vasodilatation. Under physiologic conditions the ratio of PGI₂ to TxA₂ is around 4:1. This is responsible at least in a part for maintaining endothelial thromboresistance and hemocompatibility (*Havel et al., 1992*).

Platelet plug quickly arrests bleeding but must be reinforced by fibrin for long-term effectiveness. Fibrin reinforcement results from local stimuli to blood coagulation, the exposed collagen of damaged vessel, the membranes and released contents of platelets (*O'Reilly, 1991*).

Blood Coagulation System: